Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis' (NVS) second-quarter earnings and sales beat estimates. Based on strong momentum, the company raises its operating income outlook for 2024.

Novartis (NVS) Tops on Q2 Earnings, Ups Operating Income View

Novartis topped Q2 views and lifted guidance. Shares eased after a four-month run.

Novartis Reports Near 40% Margin In Q2; Shares Slide

Merck

Merck's long-term prospects look strong despite a major incoming patent cliff. Novartis' diversified lineup and pipeline, solid results, and dividend record make it an excellent pick.

2 Magnificent Stocks to Buy With $500

Key growth drivers from the quarter included Entresto and Kesimpta drugs

Novartis lifts guidance again as demand climbs for top drugs

Swiss drugmaker Novartis raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions of drugs including heart failure treatment Entresto and Kesimpta for multiple sclerosis.

Novartis raises 2024 profit guidance for second time

Ad hoc announcement pursuant to Art. 53 LR Q2 net sales grew +11% (cc 1 , +9% USD) with core operating income up +19% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+28% cc), Kesimpta (+65% cc), Cosentyx (+22% cc), Kisqali (+50% cc), Leqvio (+134% cc) and Pluvicto (+44% cc) Core operating income margin 39.6%, +270 basis points (cc), mainly driven by higher net sales Q2 operating income grew +47% (cc, +43% USD) and net income up +49% (cc, +43% USD) Q2 core EPS grew +21% (cc, +17% USD) to USD 1.97 Q2 free cash flow 1 of USD 4.6 billion (+40% USD) driven by higher net cash flows from operating activities H1 sales up +11% (cc, +9% USD) and core operating income up +21% (cc, +16% USD) Q2 selected innovation milestones: Fabhalta (iptacopan) received EU, Japan and China approval for the treatment of PNH Lutathera approved by FDA for pediatric GEP-NET patients (≥12 years) Scemblix filing for 1L CML accepted by FDA; received Breakthrough Therapy designation Atrasentan FDA filing accepted for the treatment of adult patients with IgAN Kisqali NATALEE updated data showed continued clinical benefit with median follow-up ~4 years Full-year 2024 guidance raised for core operating income based on strong momentum 2 Net sales expected to grow high-single to low double-digit (unchanged) Core operating income expected to grow mid- to high teens (from low double-digit to mid-teens) Basel, July 18, 2024 – commenting on Q2 2024 results, Vas Narasimhan, CEO of Novartis, said: “Novartis delivered a strong Q2, with net sales up 11% and core operating income margin approaching 40%.

Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance

Gigacloud Tech

iShares International Select Dividend ETF

U.S. stock indices have reached new highs, driven by strong corporate earnings, especially in technology. Meanwhile, many non-U.S. stocks have lagged so far in 2024.

3 Global Stocks to Buy to Escape the Volatility on Wall Street

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Novartis (NVS) is a Strong Value Stock

Novartis AG will report second quarter results this week. The company should report another strong quarter, with growth led by key products such as Entresto, Kesimpta, Kisqali, Cosentyx, and Leqvio. I expect a modest revenue and EPS beat, with NVS maintaining the full-year guidance for both revenues and core operating income.

Novartis Q2 Earnings Preview: Positive Fundamental Trends Should Continue

Abbott Labs

Gilead Sciences

HCA Healthcare

Medtronic

Pfizer

Tenet Healthcare

Over the years, especially the past three, I have become more cautious about the technology sector's blatant overvaluation. Nevertheless, it is difficult to ignore the capabilities of companies such as Nvidia (NASDAQ: NVDA ) and their innovative solutions for AI.

The 7 Most Undervalued Healthcare Stocks to Buy in July 2024

Recursion Pharmaceuticals

While the pairing of artificial intelligence and healthcare may sound like something straight out of a science fiction movie, there are several avenues through which the high-speed data processing offered by AI can improve patient outcomes. From more precise diagnosis to pandemic modeling, the large-scale algorithmic models we call AI can help the world of medicine immensely.

3 Healthcare Stocks Injecting AI for Big Gains

Community Bank System

Cullen/Frost Bankers

Chevron

Kimberly-Clark

Altria

National Fuel Gas

Old Republic International

Polaris

Target

Stocks keep setting record highs, with valuations becoming steadily more challenging. But even at record highs, there are plenty of blue-chip bargains to buy. Free cash flow yield is a gold standard of valuation. It combines yield and quality and, if combined with growth, creates the ultimate PEG ratio, popularized by Peter Lynch. This article highlights 10 high-yield dividend aristocrats with the lowest PEG ratios, 6X better than the aristocrats and 3X better than US stocks.

10 Dividend Aristocrat Bargain Buys: High Yields And Low PEG Ratios

GlaxoSmithKline

Novo Nordisk

Undervalued pharma stocks can make good investments, whether during times of a booming economy or a faltering one. That is because people will still need medications and healthcare services regardless of the ongoing economic conditions.

The 3 Most Undervalued Pharma Stocks to Buy in July 2024

Biogen

Immunic Inc

Immunic Inc (NASDAQ:IMUX) told investors it has appointed a former Novartis and Biogen executive as its new chief operating officer to lead internal efforts to prepare for the potential launch of vidofludimus calcium. Jason Tardio will join the company in the newly created role of COO and president from July 12, the biotechnology company said.

Immunic appoints ex Novartis and Biogen exec as new COO to lead vidofludimus calcium launch

Automatic Data Processing

C.H. Robinson Worldwide

Enterprise Products Partners

PPG Industries

Tompkins Financial

The market remains near record highs with the best-ever presidential election year return and 13th-best S&P return through the first half of the year. Free cash flow yield is the best valuation metric since 1990, averaging 17.6% annual returns for the most undervalued companies over the last 33 years. Screening for high free cash flow yield dividend aristocrats can provide a diversified portfolio of quality, income dependability, growth, and value.

9 High-Yield Dividend Aristocrat Bargain Buys

Amazon

Brookfield Asset Management

British American Tobacco

Carlisle Companies

Ecolab

Enbridge

Alphabet

Mastercard

Public Storage

WEC Energy Group

Stocks have been on fire since October lows, with many investors worried about bubbles and looming corrections. Even with the market at an all-time high, there are always extraordinary blue-chip bargains to buy. Optimal portfolio design with 11 sector Ultra SWAN blue-chip max volatility-adjusted return potential can provide good returns and lower volatility in bear markets.

11 Sleep Well At Night Blue-Chip Bargains For Today's Overvalued Market

Amgen

bluebird bio

Bristol-Myers

Neurocrine Biosciences

Ultragenyx Pharmaceutical

Biotech stocks operate under a core ethos. While there's been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing is more valuable than one's health.

7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline

Pending regulatory submission, Fabhalta (iptacopan) could become the first approved therapy for C3G, addressing a significant unmet need in nephrology, according to Spherix Global Insights. Pending regulatory submission, Fabhalta (iptacopan) could become the first approved therapy for C3G, addressing a significant unmet need in nephrology, according to Spherix Global Insights.

Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment

Italy's antitrust regulator said on Thursday it had launched a probe into several pharmaceutical companies, including Novartis , for having potentially restricted competition in the sale of a drug for eye conditions.

Novartis and others face Italy antitrust probe over eye drug

Centene

United Therapeutics

When it comes to seeking discounts, investors may do well with undervalued healthcare stocks. Primarily, that's because with this sector, you're dealing with a permanently relevant narrative.

The 3 Most Undervalued Healthcare Stocks to Buy in June 2024

Novartis AG (NYSE:NVS ) Investor Event at ASCO Conference Call June 2, 2024 7:00 PM ET Company Participants Parag Mahanti - Investor Relations Shreeram Aradhye - President of Global Drug Development and Chief Medical Officer Jeff Legos - Global Head of Oncology & Hematology Drug Development Reshema Kemps-Polanco - Chief Commercial Officer of U.S. Business Rodney Gillespie - International Therapeutic Area Head, Oncology Novartis Conference Call Participants Emmanuel Papadakis - Deutsche Bank Steve Scala - TD Cowen Emily Field - Barclays Mark Purcell - Morgan Stanley Seamus Fernandez - Guggenheim Security Peter Welford - Jefferies Parag Mahanti Hi, everyone. Thank you so much for joining us at the Novartis Investor Event at ASCO 2024.

Novartis AG (NVS) Investor Event at ASCO Conference Call (Transcript)

Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.

Novartis (NVS) Reports Positive Long-Term Data on CSU Drug

Swiss drugmaker Novartis said patients with a type of leukemia who took its Scemblix had a significantly better response and a lower dropout rate than those who received current standard-of-care drugs in a late-stage study with details presented on Friday.

Novartis leukemia drug more effective than older treatments in trial

Basel, May 31, 2024 – Novartis today presents positive results from the pivotal Phase III ASC4FIRST trial as a late-breaking abstract at the 2024 American Society of Clinical Oncology (ASCO) meeting. Scemblix® (asciminib) demonstrated superior major molecular response (MMR) rates at week 48 compared to investigator-selected standard-of-care (SoC) tyrosine kinase inhibitors (TKIs) imatinib, nilotinib, dasatinib and bosutinib, and compared to imatinib alone in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP)1. Scemblix also showed a numerical improvement in MMR at week 48 vs. second generation (2G) TKIs (nilotinib, dasatinib and bosutinib)1. Additionally, Scemblix demonstrated a favorable safety and tolerability profile, with fewer adverse events (AEs) and treatment discontinuations vs. both imatinib and 2G TKIs1.

Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML

Basel, May 31, 2024 – Novartis today announced new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective Bruton's tyrosine kinase (BTK) inhibitor, in chronic spontaneous urticaria (CSU)1. In the pivotal Phase III studies, REMIX-1 and REMIX-2, remibrutinib treatment showed significant symptom improvement early, which was sustained up to Week 52, in patients with CSU who remained symptomatic despite second-generation H1-antihistamine use1. These data are being presented at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain, May 31–June 3.

Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria

News for Novartis Stock (NVS)